focus -WSS

focus

author：hotspot 2025-10-01 11:46:53 - browse：482

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： What is STAT's opinion section for?

WSS

Medicare Advantage 2025 payments will dip, Biden administration says

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

What health policies could hitch a ride on a spending bill?

Study: Black kids more likely to die after surgery than white kids

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Readout Newsletter: Zepbound, Valneva's vaccine, and more

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Psychedelics group wrestles with new pharma identity

Oral obesity drug from Viking Therapeutics hits key early target

Alkermes shareholders re

Medical school prerequisites are outdated

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Malaria cases in Florida and Texas: Here’s what you need to know

Hundreds died while taking an arthritis drug, but nobody alerted patients

The cancer drug shortage isn’t new — and neither are the solutions

Overprescribed: High cost isn't America's only drug problem

Wikipedia

Covid silver lining: Unprecedented look at human immune system

What is STAT's opinion section for?

Ventyx halts psoriasis drug development after lackluster trial results

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Gut bacteria may contribute to kidney autoimmunity, study finds

What health policies could hitch a ride on a spending bill?

hotspot

leisure time

entertainment

explore